Paul Tudor Jones Esperion Therapeutics, Inc. Call Options Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
174Shares Held
125MCall Options Held
2.08MPut Options Held
1.01M-
Orbimed Advisors LLC San Diego, CA13.7MShares$28.7 Million0.83% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$20.8 Million0.42% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.13MShares$19.1 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.83MShares$18.4 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT8MShares$16.7 Million5.25% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $139M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...